SCHEMBL4861149

SCHEMBL4861149

CN(CCCNC(=O)CCl)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.57
BCHE P06276 1/20 0.55
TSHR P16473 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C19 P33261 2/20 0.49
GFER P55789 2/20 0.49
ALOX15 P16050 1/20 0.49
CNR1 P21554 1/20 0.49
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
CYP1A2 P05177 1/20 0.47
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
THRB P10828 1/20 0.46
ACKR3 P25106 1/20 0.45
KDM4E B2RXH2 1/20 0.45
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9099535 0.88 USP2 (0.57) USP2BCHETSHRCYP3A4CYP2D6
SCHEMBL13415823 0.84 MTNR1A (0.66) USP2BCHETSHRCNR1MTNR1A
SCHEMBL8285864 0.82 HDAC6 (0.55) USP2BCHETSHRCNR1MTNR1A
SCHEMBL9549340 0.81 DNM1 (0.62) USP2BCHEGAA
SCHEMBL13396996 0.80 CYP2C19 (0.59) USP2BCHETSHRCYP3A4CYP2D6
SCHEMBL28417610 0.80 BCHE (0.54) USP2BCHETSHRCYP3A4CYP2D6
SCHEMBL29420323 0.79 BCHE (0.53) USP2BCHETSHRCYP3A4CYP2D6
SCHEMBL2012086 0.78 ACKR3 (0.54) USP2BCHETSHRCYP3A4CYP2D6
SCHEMBL9100684 0.77 CKS1B (0.52) USP2BCHETSHRCYP3A4CYP2D6
SCHEMBL9244171 0.77 MMP2 (0.50) USP2BCHEGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A USP2 4428/4885BCHE 2081/4885TSHR 3836/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A USP2 4411/4885BCHE 2145/4885TSHR 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.